Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [3] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at achieving precise and transient single base edits [3] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT [1] - Vineet Agarwal, CFO, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in the conference [1] - A live webcast of the presentation will be available on Korro's website, with a replay accessible for 30 days following the event [2]
Korro to Present at the Jefferies London Healthcare Conference